KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) Gross Profit (2020 - 2023)

AbCellera Biologics (ABCL) has disclosed Gross Profit for 4 consecutive years, with $9.2 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Gross Profit fell 53.98% year-over-year to $9.2 million, compared with a TTM value of $38.0 million through Dec 2023, down 90.92%, and an annual FY2024 reading of $28.8 million, down 24.17% over the prior year.
  • Gross Profit was $9.2 million for Q4 2023 at AbCellera Biologics, up from $6.6 million in the prior quarter.
  • Across five years, Gross Profit topped out at $271.9 million in Q1 2022 and bottomed at $4.2 million in Q1 2020.
  • Average Gross Profit over 4 years is $64.8 million, with a median of $16.9 million recorded in 2022.
  • The sharpest move saw Gross Profit surged 4230.12% in 2021, then tumbled 96.9% in 2023.
  • Year by year, Gross Profit stood at $205.7 million in 2020, then plummeted by 33.15% to $137.5 million in 2021, then plummeted by 85.5% to $19.9 million in 2022, then tumbled by 53.98% to $9.2 million in 2023.
  • Business Quant data shows Gross Profit for ABCL at $9.2 million in Q4 2023, $6.6 million in Q3 2023, and $13.8 million in Q2 2023.